Kymera Therapeutics Inc (NASDAQ: KYMR) kicked off on Monday, up 41.55% from the previous trading day, before settling in for the closing price of $66.62. Over the past 52 weeks, KYMR has traded in a range of $19.44-$68.80.
Annual sales at Healthcare sector company slipped by -26.36% over the past five years. While this was happening, its average annual earnings per share was recorded -17.95%. With a float of $59.57 million, this company’s outstanding shares have now reached $71.74 million.
Kymera Therapeutics Inc (KYMR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kymera Therapeutics Inc is 17.20%, while institutional ownership is 97.75%. The most recent insider transaction that took place on Dec 08 ’25, was worth 448,823. In this transaction Director of this company sold 5,000 shares at a rate of $89.76, taking the stock ownership to the 0 shares. Before that another transaction happened on Dec 08 ’25, when Company’s Chief Executive Officer sold 100,000 for $89.17, making the entire transaction worth $8,917,000. This insider now owns 660,482 shares in total.
Kymera Therapeutics Inc (KYMR) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.89 earnings per share (EPS), lower than consensus estimate (set at -0.79) by -0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -17.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.94% during the next five years compared to -26.36% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Take a look at Kymera Therapeutics Inc’s (KYMR) current performance indicators. Last quarter, stock had a quick ratio of 7.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 155.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.60, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -3.81 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc (NASDAQ: KYMR) saw its 5-day average volume 1.98 million, a positive change from its year-to-date volume of 0.77 million. As of the previous 9 days, the stock’s Stochastic %D was 61.64%.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 86.89%, which indicates a significant increase from 78.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.86 in the past 14 days, which was higher than the 2.59 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $61.97, while its 200-day Moving Average is $44.25. Nevertheless, the first resistance level for the watch stands at $102.66 in the near term. At $111.03, the stock is likely to face the second major resistance level. The third major resistance level sits at $119.05. If the price goes on to break the first support level at $86.27, it is likely to go to the next support level at $78.25. The third support level lies at $69.89 if the price breaches the second support level.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
The company with the Market Capitalisation of 6.78 billion has total of 71,949K Shares Outstanding. Its annual sales at the moment are 47,070 K in contrast with the sum of -223,860 K annual income. Company’s last quarter sales were recorded 2,760 K and last quarter income was -82,180 K.
